Tucson, Ariz.-based HTG Molecular Diagnostics this week announced the availbility of two new multiplexed assays for drug and oncology research.
The 47-gene Edge DMPK Assay enables researchers to characterize drug metabolism in pre-clinical studies. The company also released its Edge TOA Assay, which measures the expression levels of 32 of the most commonly assayed oncogenes in fresh or fixed biological specimens.
Both new offerings rely on HTG's quantitative nuclease protection assay, or qNPA, technology, and are processed using its automated Edge system for gene expression profiling of formalin-fixed, paraffin-embedded samples.